Barclays PLC Grows Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

Barclays PLC grew its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 587.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 114,075 shares of the company’s stock after purchasing an additional 97,493 shares during the quarter. Barclays PLC owned approximately 0.17% of Perspective Therapeutics worth $1,523,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. nVerses Capital LLC purchased a new position in Perspective Therapeutics during the third quarter worth about $57,000. US Bancorp DE increased its stake in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares during the last quarter. Victory Capital Management Inc. acquired a new position in shares of Perspective Therapeutics during the 2nd quarter valued at about $117,000. Point72 DIFC Ltd purchased a new position in shares of Perspective Therapeutics during the 2nd quarter worth about $118,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Perspective Therapeutics in the third quarter worth approximately $137,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Insider Transactions at Perspective Therapeutics

In other news, Director Heidi Henson bought 25,975 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The shares were purchased at an average price of $3.85 per share, with a total value of $100,003.75. Following the completion of the acquisition, the director now directly owns 25,975 shares in the company, valued at approximately $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Johan M. Spoor bought 8,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was purchased at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the transaction, the chief executive officer now directly owns 36,257 shares of the company’s stock, valued at $136,688.89. This trade represents a 28.31 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by corporate insiders.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $3.19 on Friday. The firm has a 50-day moving average price of $6.86 and a two-hundred day moving average price of $10.77. Perspective Therapeutics, Inc. has a 52-week low of $2.70 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Sell-side analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CATX shares. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. UBS Group began coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 target price on the stock. Royal Bank of Canada dropped their price target on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday, November 25th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 price target (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Perspective Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.